Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical company whose entire valuation rests on ivonescimab, a PD-1 x VEGF bispecific antibody it licenses from China's Akeso and develops for North America, Europe, Japan and other territories. The stock closed Friday at $14.15 and last traded at $12.79, a decline of 9.61% — a sharp downside move that confirmed the bearish reaction to a weekend regulatory setback. Before the opening bell, shares had traded near $11.70, a fresh 52-week low. The immediate cause was verified: the FDA issued a Complete Response Letter for the company's first U.S. marketing application, and investors are repricing the odds that ivonescimab ever reaches the American market in this indication.
On Sunday, Summit disclosed that the FDA issued a Complete Response Letter for its Biologics License Application covering ivonescimab combined with platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior EGFR tyrosine kinase inhibitor therapy. The filing had carried a mid-November action date.
The agency's objection is efficacy evidence, not safety. Regulators concluded that a statistically significant progression-free survival benefit — which the HARMONi trial delivered — does not on its own establish a positive benefit-risk profile without a statistically significant overall survival improvement. Summit noted that no approved regimen in this setting has demonstrated statistically significant overall survival, and that its own overall survival trend was positive but short of significance; post-hoc analyses with longer Western follow-up produced a 0.76 hazard ratio that the agency did not find persuasive.
The decision matters because the U.S. was the anchor of the bull case. With no approval in any licensed territory outside China, the timeline to first revenue in Summit's core markets has moved out materially, and the burden of proof shifts to the broader program — first-line lung cancer, colorectal, bladder and kidney studies.
Analyst revisions reinforced the selling. Barclays lowered its price target to $18 from $20 while keeping an Equal Weight rating, arguing the letter has limited direct valuation impact but signals a meaningfully higher FDA efficacy bar for the lung cancer program. Nomura cut Akeso to Neutral from Buy and slashed its target by roughly 32%, framing the letter as the drug's first failed overseas filing. Both notes were published before the open, consistent with the timing of the gap lower.
The reaction compounded an already weak tape in the shares. Summit fell 9.4% on Nov. 12 amid reports of commercial leadership departures ahead of the regulatory decision, then lost another 6.1% on Friday, capping a weekly decline of 13.35%. That earlier selling left the stock below its 20-day and 60-day moving averages before the news broke, and positioned it to break down rather than absorb the shock. Third-quarter results — a net loss of $208.4 million, a loss of $0.26 per share and no revenue — provided no offsetting support.
Volume was heavy: roughly 2.8 million shares changed hands in the first 25 minutes of regular trading, close to half of the stock's typical full-session turnover of about 6.1 million shares, on top of a very active premarket. The move was idiosyncratic. The biotech sector weakened modestly, with the XBI down about 1.6% and the IBB down about 0.8%, while the broad S&P 500 proxy slipped roughly 0.9% — a fraction of Summit's decline. Technically, the stock broke to a new 52-week low intraday and now sits approximately 56% below its April 2026 high near $29.23, with both short- and medium-term moving averages far overhead.
The score runs from 0, meaning no meaningful news and a routine move for the stock, to 100, meaning transformative news and an extreme, rare move. This event lands at 55 out of 100. The verified news was substantial — a complete response letter for the company's lead asset in its first major market is a major, thesis-altering regulatory event for a pre-revenue company. The price reaction, however, was less extreme than the headlines imply: the 9.61% decline was roughly 2.4 times the stock's average daily move, and moves of similar or greater magnitude have occurred six times in the last 60 sessions. Strong news paired with a large but not unprecedented move produces a mid-range score.
Attention shifts to how quickly management requests a meeting with regulators and what a resubmission would require — a new trial, longer follow-up, or an alternative endpoint. The larger catalyst pipeline remains intact: HARMONi-3 in first-line lung cancer, HARMONi-7, HARMONi-GI3 in colorectal cancer and HARMONi-GU1 in bladder cancer all continue to enroll, and any of those readouts could reset the narrative. Financially, Summit ended the third quarter with $629.8 million in cash and investments, bolstered by a $2.0 billion AstraZeneca (AZN) equity investment, though shareholders recently approved doubling authorized shares to 2.0 billion, keeping dilution risk in view. Risks include further analyst target cuts, competitive pressure in first-line lung cancer, and the possibility that a broader FDA efficacy standard spills into other ivonescimab programs.
Tickeron's Trending AI Robots page is a curated window into that universe: the platform offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced here. Bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the featured list rotates as market conditions change. For readers tracking volatile names like Summit, it is a practical way to see which automated approaches are working right now — worth a look before the next session opens.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for SMMT moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for SMMT moved above the 200-day moving average on November 04, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +25.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 244 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 91 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
SMMT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMMT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SMMT entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SMMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.679) is normal, around the industry mean (3.592). P/E Ratio (-14.712) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel medicines
Industry Biotechnology